What We’re Doing

CorriXR is developing a new paradigm for the treatment of solid tumors using a proprietary CRISPR/Cas biomolecular tool that selectively targets the NRF2 pathway — a master regulator of tumor survival and treatment resistance.

Our preclinically validated lead program CXR101, is focused on head and neck squamous cell carcinoma (HNSCC). HNSCC is the 7th leading cause of cancer in the U.S., with 50% of patients experiencing recurrence within 2 years of diagnosis. CorriXR’s approach is designed to overcome resistance associated with standard of care, optimizing all treatment modalities for improved safety and efficacy.

By disabling NRF2, CXR101 is designed to reprogram the tumor microenvironment and disable drug resistance pathways. Delivery is achieved via a proven lipid nanoparticle (LNP) system paired with localized administration to ensure precise engagement at the tumor site while minimizing off-target effects.

Our proprietary in vivo gene editing platform has broad applicability for 30+ squamous cell carcinoma indications with the potential to enhance tumor cell stress response to all standard of care treatments and improve patient outcomes.